Incannex Healthcare Inc. (NASDAQ: IXHL) announced that it has regained compliance with Nasdaq’s minimum bid‑price requirement, satisfying Listing Rule 5550(a)(2). The company’s common stock closed at $1.00 or higher for eleven consecutive business days, from February 27 through March 13, 2026, thereby ending the Nasdaq compliance extension it had received earlier in the year and restoring full Nasdaq Capital Market listing status.
The compliance was achieved in part after the company completed a 1‑for‑30 reverse stock split that took effect shortly before the bid‑price milestone. The split helped lift the per‑share price above the $1.00 threshold and was a key step in meeting the Nasdaq rule, which requires a minimum bid price for 30 consecutive business days to avoid a deficiency notice.
Incannex highlighted its strong balance‑sheet position, reporting approximately $75 million in cash, no debt, and a disciplined development strategy. While the company remains a clinical‑stage biopharma with significant cash burn—typical for a firm investing heavily in its pipeline—its cash reserve provides a cushion to fund ongoing research and development without immediate financing concerns.
The company’s pipeline focuses on two lead clinical programs: IHL‑42X, an oral pharmacotherapy for obstructive sleep apnea, and PSX‑001, a psilocybin‑assisted psychotherapy for generalized anxiety disorder. CEO Joel Latham said, “We are pleased to have regained compliance with Nasdaq’s minimum bid price requirement, which reinforces our continued listing on the Nasdaq Capital Market and removes a technical overhang that has weighed on the Company.” He added, “With approximately $75 million in cash, no debt, and a disciplined development strategy, we believe Incannex is exceptionally well positioned to advance our pipeline of differentiated clinical programs.”
By eliminating the Nasdaq compliance overhang, Incannex removes a significant risk factor that had weighed on investor sentiment. The company’s restored listing status, combined with its cash position and focused pipeline, positions it to de‑risk its development programs and pursue long‑term value creation for patients and shareholders.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.